Clinical characteristics

All CasesaPre-ipi approvalPost-ipi approvalPost-ipi approval
(n = 300)(n = 94)(n = 206)(n = 206)
ICI TreatedICI Not Treated
Age at initial cutaneous melanoma diagnosis (Years, %)(n = 160)(n = 46)
  < 309 (03.0)5 (05.3)4 (01.9)2 (01.3)2 (04.3)
 30–3925 (08.3)11 (11.7)14 (06.8)9 (05.6)5 (10.9)
 40–4949 (16.3)15 (16.0)34 (16.5)26 (16.3)8 (17.4)
 50–5969 (23.0)25 (26.6)44 (21.4)37 (23.1)7 (15.2)
 60–6968 (22.7)17 (18.1)51 (24.8)40 (25.0)11 (23.9)
 70–7951 (17.0)13 (13.8)38 (18.4)31 (19.4)7 (15.2)
  ≥ 8029 (09.7)8 (08.5)21 (10.2)15 (09.4)6 (13.0)
 Mean5956606158
Year of diagnosis (Range)1974–20161974–20101989–20161990–20161989–2016
Sex
 Female111 (37.0)36 (38.3)75 (36.4)53 (33.1)22 (47.8)
 Male189 (63.0)58 (61.7)131 (63.6)107 (66.9)24 (52.2)
Race
 White293 (97.7)94 (100.0)199 (96.6)154 (96.3)45 (97.8)
 Other2 (06.0)0 (00.0)2 (01.0)1 (00.6)1 (02.2)
 Unknown5 (01.7)0 (00.0)5 (02.4)5 (03.1)0 (00.0)
Vital status at last follow up
 Alive136 (45.3)16 (17.0)120 (58.3)92 (57.5)28 (60.9)
 Dead164 (54.7)78 (83.0)86 (41.7)68 (42.5)18 (39.1)
Year of bx proven Stage IV disease (range)1992–20171992–20112011–20172011–20172011–2017
Months of follow up (Median)b16.216.516.216.215.5
  < 113 (04.3)0 (00.0)13 (06.3)10 (06.3)3 (06.5)
 3122 (40.7)0 (00.0)122 (59.2)104 (65.0)18 (39.1)
 674 (24.7)3 (03.2)71 (34.5)46 (28.8)25 (54.3)
 1042 (14.0)42 (44.7)0 (00.0)0 (00.0)0 (00.0)
  > 1049 (16.3)49 (52.1)0 (00.0)0 (00.0)0 (00.0)
 Median4.41032.84.2
Years from diagnosis to bx proven Stage IV disease (Median)1.11.5110.7
Received BRAF TKI (Yes, %)25 (08.3)0 (00.0)25 (12.1)19 (11.9)6 (13.0)
Mo from specimen collection to BRAF TKI (Median)6·5N/A6·586
Checkpoint inhibitor
 Ipilimumab72 (45.0)N/A
 Pembrolizumab68 (42.5)N/A
 Nivolumab7 (04.4)N/A
 Ipilimumab + Nivolumab13 (08.1)N/A
Time to progression (median days)77.5N/A
Progression free survival (median days)129.5N/A

aAll cases are metastatic and no cutaneous samples included. bFor pre-ipi approval patients follow-up is the number of months from date of specimen collection (bx proven Stage IV disease) to last date of follow up or date of death, and for post-ipi approval patients represents the number of months from date of first dose of checkpoint inhibitor to last date of follow up or date of death